This cohort study evaluated biliary outcomes (e.g., gallstones, cholecystitis, biliary events) associated with GLP-1 receptor agonist use in adolescents and young adults aged 12–21 years with overweight or obesity.
Full text is under embargo until August 31, 2027; only the abstract is publicly available, so specific results, methods, sample size, comparators, and effect sizes cannot be verified or reported.
Explore related topics
